EFFECTS OF SOME DOPAMINE ANTAGONISTS ON SPATIAL MEMORY PER-FORMANCE IN RATS - EXPERIMENTAL RESEARCH

Authors

  • Gabriela RUSU University of Medicine and Pharmacy “Grigore T. Popa”- Iasi
  • Gratiela POPA University of Medicine and Pharmacy “Grigore T. Popa”- Iasi
  • Lacramioara OCHIUZ University of Medicine and Pharmacy “Grigore T. Popa”- Iasi
  • M. NECHIFOR University of Medicine and Pharmacy “Grigore T. Popa”- Iasi
  • Liliana TARTAU University of Medicine and Pharmacy “Grigore T. Popa”- Iasi

Keywords:

SCH-23390, MELPERONE, Y-MAZE TEST, MEMORY

Abstract

Dopamine is a neurotransmitter with an important role in forming long-lasting memories for some time, especially in episodic memory. Literature data show that dopamine receptor stimulation may be detrimental to spatial working memory functions in lab animals. (R)-(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride derivative - SCH-23390 is a synthetic compound that acts as a selective, high-affinity antagonist of D1 receptors. Experimental studies suggest that SCH 23390 may prevent the spatial working memory disturbances induced by the active substances of marijuana. Melperone is an atypic antipsychotic drug presenting also dopaminergic D2 and 5-HT2A receptor antagonistic activity. This neuroleptic agent is used in the treatment of some types of schizophrenia. Aim: Experimental research on the effects of two dopamine receptor antagonists on spatial memory performance in rats. Material and methods: The experiment was carried out in white Wistar rats (200-250g), divided into 3 groups of 7 animals each, treated intraperitoneally with the same volume of solution for 14 days, as follows: Group I (Control): saline solution 0.1ml/10g kbw; Group II (coded SCH): SCH-23390 0.3 mg/kbw; Group III (coded MLP): melperone 2 mg/kbw. The dopaminergic agent spatial memory performance was assessed by recording spontaneous alternation behavior in a single session in Y-maze. Each animal was placed at the end of one arm and allowed to move freely through the maze during an 8 min session. Alternation was defined as a consecutive entry in three different arms. The alternation percentage was computed with the following formula: number of alternations divided by total number of arm visits minus 2. Data were presented as +/- standard deviation and significance was tested by SPSS Statistics for Windows version 13.0 and ANOVA method. P-values less than 0.05 were considered statistically significant compared to those in the control group. Experimental researches were carried out in compliance with the regulations of our University Committee for Research and Ethical Issues. Results: SCH-23390 (0.3 mg/kbw) and melperone (2 mg/kbw) intraperitoneal injection for 14 days determined a statistically significant (p<0.05 and p<0.01, respectively) increase in spontaneous alternation rate (compared to controls in Y-maze test). Conclusions: Our research revealed that the 14 consecutive days administration of these two dopamine receptor antagonists was associated with the improvement of short-term memory in rats, more intense for SCH-23390 compound.

Author Biographies

  • Gabriela RUSU, University of Medicine and Pharmacy “Grigore T. Popa”- Iasi

    Faculty of Medicine
    Ph.D. student

  • Gratiela POPA, University of Medicine and Pharmacy “Grigore T. Popa”- Iasi

    Faculty of Pharmacy
    Discipline of Pharmaceutical Technology

  • Lacramioara OCHIUZ, University of Medicine and Pharmacy “Grigore T. Popa”- Iasi

    Faculty of Pharmacy
    Discipline of Pharmaceutical Technology

  • M. NECHIFOR, University of Medicine and Pharmacy “Grigore T. Popa”- Iasi

    Faculty of Medicine
    Discipline of Pharmacology-Algesiology

  • Liliana TARTAU, University of Medicine and Pharmacy “Grigore T. Popa”- Iasi

    Faculty of Medicine
    Discipline of Pharmacology-Algesiology

References

1. Bäckman L., Nyberg L., Lindenberger U., Li S-C., Farde L., The correlative triad among aging, do-pamine, and cognition: Current status and future prospects. Neuro Biobehav Rev 2006; 30: 791-807.
2. Bourne JA, SCH 23390: the first selective dopamine D1-like receptor antagonist, CNS Drug Rev, 2001, 7(4): 399-414.
3. Christensen A.V., Arnt J., Hyttel J., Larsen J.J., Svendsen O., Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics, Life Sci, 1984, 16; 34(16): 1529-1540.
4. Sumiyoshi T, Meltzer HY, Jayathilake K, Melperone, an atypical antipsychotic drug, in the treatment of schizophrenia: dose-response analysis on effectiveness and tolerability, and efficacy for treatment-resistant schizophrenia and cognitive function, Intern Clin Psychopharm, 2004; 19(3): 184-188.
5. Pöldinger WJ, Melperone in low doses in anxious neurotic patients. A double-blind placebo-controlled clinical study, Neuropsychobiol, 1984, 11(3): 181–186.
6. Whiskey E., Vavrova M., Gaughran F., Taylor D., Melperone in Treatment-Refractory Schizophrenia: A Case Series, Therap Adv in Psychopharm, 2011; 1(1): 19–23.
7. Meltzer HY, Sumiyoshi T, Jayathilake K., Melperone in the treatment of neuroleptic-resistant schizo-phrenia, Psychiatry Res. 2001; 105(3): 201-209.
8. Björklund A., Dunnett S.B., Dopamine neuron systems in the brain: an update. Trends Neurosci, 2007; 30: 194-202.
9. Baker M., Animal models: Inside the minds of mice and men. Nature 2011; 475: 123-128.
10. Hughes RN. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmaco-logical investigations of memory. Neurosc Biobehav Rev, 2004; 28: 497–505.
11. Guidelines on Euthanasia (Formerly Report of the AVMA Panel on Euthanasia), 2007.
12. Rusu G., Nechifor M., Lupusoru C.E., Tartau L., Effects of some dopamine agents on modulation of memory processes performance in rats, Rev. Med. Chir., Iaşi, 2013; 117(4): 951-956.
13. Bromberg-Martin E.S., Matsumoto M., Hikosaka O., Dopamine in motivational control: rewarding, aversive, and alerting, Neuron, 2010; 68 (5): 815-834.
14. Schultz W., Multiple dopamine functions at different time courses. Rev Neurosci, 1997, 30, 259-288.
15. Burgess N., Spatial cognition and the brain. Ann New York Acad Sci, 2008; 1124: 77-97.
16. Newman-Tancredi A., Cussac D., Audinot V., Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor, J Pharmacol Exp Ther, 2002; 303 (2): 805-814.
17. Bird C.M., Burgess N., The hippocampus and memory: insights from spatial processing, Nature Rev Neurosci, 2008; 9: 182–194.
18. Rodrigues L.C., Conti C.L., Nakamura-Palacios E.M., Clozapine and SCH 23390 prevent the spatial working memory disruption induced by Δ9-THC administration into the medial prefrontal cortex, Brain Res, 2001; 1382: 230-237.
19. Bergson C., Mrzljak L., Smiley J.F., Pappy M., Levenson R., Goldman-Rakic P.S. Regional, cellular and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain, J Neurosc, 1995;15: 7821-7836.
20. Seeman P, Corbett R, Van Tol HH, Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors, Neuropsychopharm, 1997; 16(2): 93-110.
21. Karlsson S., Nyberg L., Karlsson P., Fischer H., Thilers P., MacDonald S., Bäckman L., Modulation of striatal dopamine D1 binding by cognitive processing, Neuroimage, 2009; 48: 398-404.
22. Undieh A.S., Pharmacology of signaling induced by dopamine D1-like receptor activation. Phamacol & Ther, 2010; 128: 37-60.
23. Sibley D.R., Monsma F.J.Jr., Shen Y., Molecular neurobiology of dopaminergic receptors. Intern Rev Neurobiol, 1993; 35: 391-415.
24. Zhang J., Xiong B., Zhen X., Zhang A., Dopamine D1 receptor ligands: Where are we know and where are we going. Med Res Rev, 2009; 29: 272-294.
25. Centonze D., Grande C., Saulle E., Martín A.B., Gubellini P., Pavón N., Calabresi P., Distinct roles of D1 and D5 dopamine receptors in motor activity and synaptic plasticity. J Neurosci, 2003; 23: 8506-8512.
26. Seeman P., Van Tol H.H.M., Dopamine receptor pharmacology, Trends Pharmacol Sci, 1994; 15: 264-270.
27. Bardget ME, Depenbrock M., Downs N., Points M., Green L., Dopamine modulates effort-based decision-making in rats, Behav Neurosci, 2009; 123(2): 242-251.

Additional Files

Published

2018-05-14

Issue

Vol. 118 No. 1 (2014): The Medical-Surgical Journal

Section

BASIC SCIENCES

License

COPYRIGHT 
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.

COPYRIGHT TRANSFER FORM FOR 

REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /

THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI

We, the undersigned authors of the manuscript entitled

_____________________________________________________________________________________

_____________________________________________________________________________________

warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.

  1. we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
  2. the manuscript does not break the intellectual property rights of any other person.
  3. we have read the submitted version of the manuscript and we are fully responsible for the content.

Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):

  1. ______________________________/_________________________
  2. ______________________________/_________________________
  3. ______________________________/_________________________

N.B.  All the authors must sign this form